Steven Cohen's FOLD Position Overview
Steven Cohen (via Point72 Asset Management, L.P.) currently holds 2.07 M shares of Amicus Therapeutics, Inc. (FOLD) worth $29.45 M, representing 0.03% of the portfolio. First purchased in 2014-Q3, this long-term strategic position has been held for 38 quarters.
Based on 13F filings, Steven Cohen has maintained a strategic position in FOLD, demonstrating sustained confidence in this investment. Largest addition occurred in Q2 2023, adding 4.75 M shares. Largest reduction occurred in Q3 2023, reducing 6.05 M shares.
Analysis based on 13F filings available since 2013 Q2
Steven Cohen's Amicus Therapeutics (FOLD) Holding Value Over Time
Track share changes against reported price movement
Quarterly Amicus Therapeutics (FOLD) Trades by Steven Cohen
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | -5.09 M | Reduce 71.10% | 2.07 M | $14.24 |
| Q3 2025 | +3.88 M | Add 118.25% | 7.16 M | $7.88 |
| Q2 2025 | +293,939 | Add 9.85% | 3.28 M | $5.73 |
| Q1 2025 | +2.99 M | New Buy | 2.99 M | $8.16 |
| Q4 2024 | -1.27 M | Sold Out | 0 | $0.00 |
| Q3 2024 | +1.27 M | New Buy | 1.27 M | $10.68 |
| Q4 2023 | -946,697 | Sold Out | 0 | $0.00 |
| Q3 2023 | -6.05 M | Reduce 86.48% | 946,697 | $12.16 |
| Q2 2023 | +4.75 M | Add 211.27% | 7 M | $12.56 |
| Q1 2023 | +2.25 M | New Buy | 2.25 M | $11.09 |
| Q4 2022 | -1.65 M | Sold Out | 0 | $0.00 |
| Q3 2022 | +528,500 | Add 47.28% | 1.65 M | $10.44 |
| Q2 2022 | +642,400 | Add 135.10% | 1.12 M | $10.74 |
| Q1 2022 | +475,500 | New Buy | 475,500 | $9.47 |
| Q3 2021 | -3.87 M | Sold Out | 0 | $0.00 |
| Q2 2021 | +3.69 M | Add 2081.00% | 3.87 M | $9.64 |
| Q1 2021 | +177,322 | New Buy | 177,322 | $9.88 |
| Q4 2020 | -1.54 M | Sold Out | 0 | $0.00 |
| Q3 2020 | +522,513 | Add 51.30% | 1.54 M | $14.12 |
| Q2 2020 | -1.22 M | Reduce 54.59% | 1.02 M | $15.08 |
| Q1 2020 | +2.24 M | New Buy | 2.24 M | $9.24 |
| Q4 2019 | -1.27 M | Sold Out | 0 | $0.00 |
| Q3 2019 | -1.76 M | Reduce 58.12% | 1.27 M | $8.02 |
| Q2 2019 | +3.03 M | New Buy | 3.03 M | $12.48 |
| Q1 2019 | -3.8 M | Sold Out | 0 | $0.00 |
| Q4 2018 | +1.47 M | Add 63.17% | 3.8 M | $9.58 |
| Q3 2018 | +1.62 M | Add 229.31% | 2.33 M | $12.09 |
| Q2 2018 | +707,300 | New Buy | 707,300 | $15.62 |
| Q1 2018 | -2.87 M | Sold Out | 0 | $0.00 |
| Q4 2017 | +1.13 M | Add 65.00% | 2.87 M | $14.39 |
| Q3 2017 | -133,654 | Reduce 7.14% | 1.74 M | $15.08 |
| Q2 2017 | -1.13 M | Reduce 37.57% | 1.87 M | $10.07 |
| Q1 2017 | +3 M | New Buy | 3 M | $7.13 |
| Q3 2015 | -916,700 | Sold Out | 0 | $0.00 |
| Q2 2015 | +742,800 | Add 427.14% | 916,700 | $14.15 |
| Q1 2015 | +173,900 | New Buy | 173,900 | $10.88 |
| Q4 2014 | -195,900 | Sold Out | 0 | $0.00 |
| Q3 2014 | +195,900 | New Buy | 195,900 | $5.95 |
Steven Cohen's Amicus Therapeutics Investment FAQs
Steven Cohen first purchased Amicus Therapeutics, Inc. (FOLD) in Q3 2014, acquiring 195,900 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Steven Cohen has held Amicus Therapeutics, Inc. (FOLD) for 38 quarters since Q3 2014.
Steven Cohen's largest addition to Amicus Therapeutics, Inc. (FOLD) was in Q2 2023, adding 7,000,900 shares worth $87.93 M.
According to the latest 13F filing for Q4 2025, Steven Cohen's firm, Point72 Asset Management, L.P., owns 2,068,454 shares of Amicus Therapeutics, Inc. (FOLD), valued at approximately $29.45 M.
As of the Q4 2025 filing, Amicus Therapeutics, Inc. (FOLD) represents approximately 0.03% of Steven Cohen's publicly disclosed stock portfolio, making it one of their key holdings.
Steven Cohen's peak holding in Amicus Therapeutics, Inc. (FOLD) was 7,156,557 shares, as reported at the end of Q3 2025.